CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
27 Pages - GMD12107
$1,500.00

Summary

Global Markets Direct’s, ‘CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the CardioVascular BioTherapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CardioVascular BioTherapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CardioVascular BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CardioVascular BioTherapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CardioVascular BioTherapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate CardioVascular BioTherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CardioVascular BioTherapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CardioVascular BioTherapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CardioVascular BioTherapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CardioVascular BioTherapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CardioVascular BioTherapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
CardioVascular BioTherapeutics, Inc. Snapshot 4
CardioVascular BioTherapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
CardioVascular BioTherapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
CardioVascular BioTherapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
CardioVascular BioTherapeutics, Inc. - Pipeline Products Glance 9
CardioVascular BioTherapeutics, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
CardioVascular BioTherapeutics, Inc. - Drug Profiles 11
CVBT-141A 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
CVBT-141B 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
CVBT-141H 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CVBT-141C 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CardioVascular BioTherapeutics, Inc. - Pipeline Analysis 17
CardioVascular BioTherapeutics, Inc. - Pipeline Products by Target 17
CardioVascular BioTherapeutics, Inc. - Pipeline Products by Route of Administration 18
CardioVascular BioTherapeutics, Inc. - Pipeline Products by Molecule Type 19
CardioVascular BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 20
CardioVascular BioTherapeutics, Inc. - Recent Pipeline Updates 21
CardioVascular BioTherapeutics, Inc. - Dormant Projects 22
CardioVascular BioTherapeutics, Inc. - Discontinued Pipeline Products 23
Discontinued Pipeline Product Profiles 23
CVBT-141E 23
CardioVascular BioTherapeutics, Inc. - Company Statement 24
CardioVascular BioTherapeutics, Inc. - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables
CardioVascular BioTherapeutics, Inc., Key Information 4
CardioVascular BioTherapeutics, Inc., Key Facts 4
CardioVascular BioTherapeutics, Inc. - Pipeline by Indication, 2014 6
CardioVascular BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014 7
CardioVascular BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8
CardioVascular BioTherapeutics, Inc. - Phase II, 2014 9
CardioVascular BioTherapeutics, Inc. - Phase I, 2014 10
CardioVascular BioTherapeutics, Inc. - Pipeline by Target, 2014 17
CardioVascular BioTherapeutics, Inc. - Pipeline by Route of Administration, 2014 18
CardioVascular BioTherapeutics, Inc. - Pipeline by Molecule Type, 2014 19
CardioVascular BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 20
CardioVascular BioTherapeutics, Inc. - Recent Pipeline Updates, 2014 21
CardioVascular BioTherapeutics, Inc. - Dormant Developmental Projects,2014 22
CardioVascular BioTherapeutics, Inc. - Discontinued Pipeline Products, 2014 23

List of Figures
CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Indication, 2014 6
CardioVascular BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014 7
CardioVascular BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8
CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Target, 2014 17
CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 18
CardioVascular BioTherapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 19
CardioVascular BioTherapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 20

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax